Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xincor Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution efforts are currently distributed across 1 distinct examiner and 1 distinct art unit. This indicates a streamlined interaction with the patent office for its active matters.
STEELE, AMBER D serves as the busiest examiner for this portfolio, managing 1 pending office action. This single action accounts for the total of 1 pending office action reported for the company, placing all current examination focus on this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 58.9% | +9.5% |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17844647 | METHODS OF TREATING NEUROLOGICAL DISEASES | STEELE, AMBER D | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Jun 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXincor Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Amber D Steele has the most, with 1 of Xincor Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.